Advertisement
Loading...

Ascletis Pharma Inc.

1672.HKHKSE
Healthcare
Biotechnology
HK$11.80
HK$-2.43(-17.08%)
Hong Kong Market is Open • 10:34
Advertisement

Ascletis Pharma Inc. (1672.HK) Stock Competitors & Peer Comparison

See (1672.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
1672.HKHK$11.80-15.89%15B-33.09-HK$0.43N/A
6160.HKHK$171.50-2.06%238.5B66.72HK$2.65N/A
1801.HKHK$80.90+8.08%144.6B154.35HK$0.54N/A
2269.HKHK$34.62+6.92%137.8B24.88HK$1.34N/A
9926.HKHK$116.00+5.07%108.6B-83.76-HK$1.41N/A
6990.HKHK$435.40-2.60%107.7B-243.16-HK$1.90N/A
1177.HKHK$4.95+2.91%89.2B33.27HK$0.15+1.80%
3759.HKHK$17.25-0.81%47.8B15.93HK$1.10+1.25%
1530.HKHK$18.52+7.36%46.3B4.67HK$3.96+1.35%
9995.HKHK$78.40-0.70%45.7B55.47HK$1.49N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

1672.HK vs 6160.HK Comparison June 2026

1672.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1672.HK stands at 15B. In comparison, 6160.HK has a market cap of 238.5B. Regarding current trading prices, 1672.HK is priced at HK$11.80, while 6160.HK trades at HK$171.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1672.HK currently has a P/E ratio of -33.09, whereas 6160.HK's P/E ratio is 66.72. In terms of profitability, 1672.HK's ROE is -0.19%, compared to 6160.HK's ROE of +0.12%. Regarding short-term risk, 1672.HK is more volatile compared to 6160.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 1672.HK.Check 6160.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions